Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03025269 · ClinicalTrials.gov registry record
Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis
A clinical trial, sponsored by University at Buffalo.
- Completed
- Registry status
- 30
- Enrollment target
NCT03025269 is a clinical trial that has completed, run by University at Buffalo. The registered enrollment target is 30 participants.
The verdict
NCT03025269 has completed, sponsored by University at Buffalo.
- COMPLETED
- Registry status
- 30 participants
- Enrollment target
Study Summary
This is a Phase IV, prospective, open-label, single-center, observational, longitudinal, single blinded study. The investigators will examine the effects of Ocrelizumab on cognitive, patient reported outcomes (PROs), quality of life (QoL), multiple sclerosis functional composite (MSFC), working status and magnetic resonance imaging (MRI) outcomes across 12 and 24 months.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-11-15 |
| Est. Completion | 2022-01-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03025269
The ClinicalTrials.gov registry entry for NCT03025269 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University at Buffalo, which has 67 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT03025269 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03025269 about?
NCT03025269 is a clinical study titled "Ocrelizumab Effects on Physiological and Cognitive Changes in Multiple Sclerosis". This is a Phase IV, prospective, open-label, single-center, observational, longitudinal, single blinded study. The investigators will examine the effects of Ocrelizumab on cognitive, patient reported outcomes (PROs), quality of life (QoL), multiple sclerosis functional composite (MSFC), working stat...
What is the current status of trial NCT03025269?
This trial is currently completed. The enrollment target is 30 participants. The study started on 2017-11-15. Estimated completion is 2022-01-08.
What interventions are being tested in trial NCT03025269?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT03025269?
This trial is sponsored by University at Buffalo, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.